Pirtobrutinib

Small molecule

Also known as LOXO-305, LY3527727

Approvedregulatory verdict

Evidence outlook

Approved: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Multiple Myeloma · Phase 1 · investigational in the US

Also approved (3)
CN
  • Jaypirca (pirtobrutinib) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, all lines of therapy regardless of prior covalent BTK inhibitor treatment
Product first approved 2026onclive.com
JP
  • Treatment of relapsed or refractory mantle cell lymphoma with resistance or intolerance to other BTK inhibitors
Product first approved 2024PMDA
EU
  • Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).
Product first approved 2023EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (7)
Chronic Lymphocytic Leukemia
NCT07220187 · SWOG Cancer Research Network
2026-08-04 – 2036-10 · Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT05254743 · Loxo Oncology, Inc.
2022-07-22 – 2028-01 · Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
What this study did
NCT04965493 · Loxo Oncology, Inc.
2021-09-20 – 2027-10 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Mantle Cell Lymphoma
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT07516093 · Nurix Therapeutics, Inc.
2026-08-03 – 2033-08 · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Phase 2 (42)
Chronic Lymphocytic Leukemia
NCT07624799 · French Innovative Leukemia Organisation
2026-09-01 – 2033-09-01 · CLL (Chronic Lymphocytic Leukemia)
What this study did
NCT06967610 · M.D. Anderson Cancer Center
2025-07-15 – 2033-06-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
What this study did
NCT06043674 · Christine Ryan
2024-01-22 – 2033-01-15 · Chronic Lymphocytic Leukemia, Richter's Transformation
What this study did
NCT07860775 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2026-09-15 – 2032-10-15 · CLL / SLL
What this study did
NCT06333262 · Inhye Ahn
2024-04-22 – 2032-07-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06812715 · Peter MacCallum Cancer Centre, Australia
2025-05-05 – 2031-05 · Chronic Lymphocytic Leukemia
What this study did
NCT05677919 · Mayo Clinic
2023-01-31 – 2030-09-03 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT07685717 · Jennifer Woyach
2026-07-13 – 2027-12-31 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT06466122 · Kerry Rogers
2024-11-07 – 2026-12-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Mantle Cell Lymphoma
NCT05833763 · Australasian Leukaemia and Lymphoma Group
2023-10-12 – 2037-04 · Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory
What this study did
NCT07285590 · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
2025-09-30 – 2032-12 · Mantle Cell Lymphoma (MCL)
What this study did
NCT07944651 · Tianjin Medical University Cancer Institute and Hospital
2026-12-08 – 2030-12-08 · Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
What this study did
NCT07207785 · Fondazione Italiana Linfomi - ETS
2026-02-01 – 2030-02-01 · Mantle Cell Lymphoma
What this study did
NCT06553872 · H. Lee Moffitt Cancer Center and Research Institute
2024-08-23 – 2029-08 · Mantle Cell Lymphoma
What this study did
NCT07684950 · Henan Cancer Hospital
2026-06-30 – 2029-04-30 · Mantle Cell Lymphoma (MCL)
What this study did
NCT06522386 · M.D. Anderson Cancer Center
2025-01-30 – 2029-02-28 · Mantle Cell Lymphoma
What this study did
NCT06263491 · M.D. Anderson Cancer Center
2024-05-29 – 2028-11-01 · Mantle Cell Lymphoma
What this study did
NCT06252675 · University of California, San Francisco
2024-06-11 – 2028-07-31 · Mantle Cell Lymphoma
What this study did
NCT05529069 · M.D. Anderson Cancer Center
2023-01-25 – 2027-04-28 · Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy
What this study did
NCT04849416 · Eli Lilly and Company
2021-05-14 – 2025-12-29 · Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT06588478 · Loxo Oncology, Inc.
2025-01-03 – 2028-12 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Other / comorbidity
NCT07548450 · University of Utah
2026-11 – 2035-11 · Waldenstrom Macroglobulinemia
What this study did
NCT05734495 · Dana-Farber Cancer Institute
2023-05-02 – 2033-01-25 · Waldenstrom Macroglobulinemia
What this study did
NCT06390956 · University of Utah
2025-02-20 – 2032-12 · Marginal Zone Lymphoma
What this study did
NCT07831395 · Institute of Hematology & Blood Diseases Hospital, China
2026-09-01 – 2031-12-31 · Richter Syndrome
What this study did
NCT06948786 · University of Washington
2025-11-17 – 2031-07-31 · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
What this study did
NCT07255963 · The First Affiliated Hospital of Soochow University
2025-11-30 – 2030-09-30 · DLBCL - Diffuse Large B Cell Lymphoma
What this study did
NCT07812493 · Pengpeng Xu
2026-09-01 – 2030-09-01 · Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic Lymphoma
What this study did
NCT07416890 · Zhejiang Cancer Hospital
2026-02-10 – 2030-08-05 · Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma
What this study did
NCT07744724 · Changzhou No.2 People's Hospital
2026-07-31 – 2030-07-31 · DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib
What this study did
NCT07917780 · German CLL Study Group
2026-06-18 – 2030-05-15 · Richter Transformation
What this study did
NCT07162181 · Eli Lilly and Company
2025-08-07 – 2030-05 · Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
What this study did
NCT07744750 · Changzhou No.2 People's Hospital
2026-08-30 – 2029-08-31 · DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZL
What this study did
NCT07774299 · Ruijin Hospital
2026-08-25 – 2029-08-25 · DLBCL
What this study did
NCT07744737 · Changzhou No.2 People's Hospital
2026-07-30 – 2029-04-30 · DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, Pirtobrutinib
What this study did
NCT07622784 · Sun Yat-sen University
2026-06 – 2028-12 · Relapsed or Refractory B-cell Lymphoma
What this study did
NCT07231952 · Memorial Sloan Kettering Cancer Center
2025-11-11 – 2028-04-11 · Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
What this study did
NCT06104683 · Loxo Oncology, Inc.
2024-05-01 – 2026-02-13 · Relapsing Multiple Sclerosis, Multiple Sclerosis
What this study did
Phase 1/2 (5)
Chronic Lymphocytic Leukemia
NCT07052695 · Inhye Ahn
2025-11-24 – 2032-12-31 · Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
What this study did
NCT05317936 · M.D. Anderson Cancer Center
2022-11-16 – 2025-10-06 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT04623541 · Genmab
2020-11-25 – 2028-02 · Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
What this study did
Other / comorbidity
NCT06721013 · Eli Lilly and Company
2025-07-30 – 2029-02 · Immune Thrombocytopenia (ITP)
What this study did
Phase 1 (17)
Chronic Lymphocytic Leukemia
NCT07428707 · National Heart, Lung, and Blood Institute (NHLBI)
2026-03-11 – 2030-03-01 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
Mantle Cell Lymphoma
NCT05990465 · Medical College of Wisconsin
2025-02-06 – 2030-07 · Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma
What this study did
Multiple Myeloma
NCT05024045 · Eli Lilly and Company
2021-09-30 – 2026-03-02 · Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell
What this study did
Other / comorbidity
NCT05176314 · Loxo Oncology, Inc.
2022-01-11 – 2022-04-20 · Healthy
What this study did
NCT06190691 · Eli Lilly and Company
2020-12-18 – 2021-12-30 · Healthy, Hepatic Insufficiency
What this study did
NCT06258174 · Eli Lilly and Company
2021-09-28 – 2021-12-22 · Healthy
What this study did
NCT06194214 · Eli Lilly and Company
2021-03-11 – 2021-06-09 · Healthy
What this study did
NCT06190678 · Eli Lilly and Company
2021-02-01 – 2021-06-04 · Healthy, Renal Insufficiency
What this study did
NCT06215521 · Eli Lilly and Company
2020-12-15 – 2021-03-31 · Healthy
What this study did
NCT06180980 · Eli Lilly and Company
2021-01-04 – 2021-03-08 · Healthy
What this study did
NCT06165146 · Eli Lilly and Company
2020-11-10 – 2020-12-30 · Healthy
What this study did
NCT06181006 · Eli Lilly and Company
2020-08-14 – 2020-12-01 · Healthy
What this study did
NCT06180954 · Eli Lilly and Company
2020-09-23 – 2020-11-06 · Healthy
What this study did
NCT05134337 · Loxo Oncology, Inc.
2020-02-12 – 2020-10-30 · Healthy Volunteers
What this study did
NCT06180967 · Eli Lilly and Company
2020-09-03 – 2020-10-20 · Healthy
What this study did
NCT05134350 · Loxo Oncology, Inc.
2020-02-06 – 2020-03-23 · Healthy Volunteers
What this study did
Phase 4 (3)
Chronic Lymphocytic Leukemia
NCT06876662 · Eli Lilly and Company
2025-05-20 – 2032-12 · Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
What this study did
NCT06876649 · Eli Lilly and Company
2025-05-20 – 2032-12 · Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
What this study did
NCT07218341 · Eli Lilly and Company
2026-03-09 – 2032-12 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Mantle Cell Lymphoma
NCT07784101 · Beijing InnoCare Pharma Tech Co., Ltd.
2026-10 – 2033-12 · Relapsed or Refractory Mantle Cell Lymphoma (MCL)
What this study did
Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT07342478 · Newave Pharmaceutical Inc
2026-04-23 – 2030-07-30 · CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed, SLL (Small Lymphocytic Lymphoma), SLL, CLL, CLL Progression
What this study did
NCT06973187 · BeOne Medicines
2025-09-04 – 2028-04-17 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Chronic Lymphocytic Leukemia
NCT03666000 · Imugene Limited
2019-03-11 – 2027-06 · Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Lymphocytic Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pirtobrutinib: this drugApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
AcalabrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
AlemtuzumabApprovedMonoclonal antibodyCD52not yet gradedNo reviewed efficacy summary in this indication
IbrutinibApprovedSmall moleculeBTKPartial signal
NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62)
ObinutuzumabApprovedMonoclonal antibodyCD20Partial signalNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
Rilzabrutinib
Approved(overall)
Small moleculeBTK
Reliable signal(overall)
No reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VenetoclaxApprovedSmall moleculeBCL-2Partial signal
NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001)
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKPartial signal
NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results).
BexobrutidegPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
NemtabrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)Phase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 2/3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MS-553Phase 1/2Small moleculeProtein kinase C-beta (PKC-beta)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(49 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pirtobrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT06466122 · CT.gov ↗
What to watch
2027 (9)
February 2027 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-02-28 · NCT06522386 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-04-28 · NCT05529069 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-07-01 · NCT06333262 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, PirtobrutinibNot yet recruiting
Est. primary completion 2027-07-30 · NCT07744737 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZLNot yet recruiting
Est. primary completion 2027-08-31 · NCT07744750 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-10 · NCT05254743 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-11 · NCT04662255 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1/2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07685717 · CT.gov ↗
What to watch
2028 (20)
January 2028 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-01-15 · NCT06043674 · CT.gov ↗
What to watch
February 2028 (2)
Phase 1/2Immune Thrombocytopenia (ITP)Recruiting
Est. primary completion 2028-02 · NCT06721013 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-02-01 · NCT07207785 · CT.gov ↗
What to watch
April 2028 (2)
Phase 2Waldenstrom Macroglobulinemia, Lymphoplasmacytic LymphomaRecruiting
Est. primary completion 2028-04-11 · NCT07231952 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-04-25 · NCT05536349 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Relapsed or Refractory B-cell LymphomaNot yet recruiting
Est. primary completion 2028-06 · NCT07622784 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-06 · NCT06588478 · CT.gov ↗
What to watch
July 2028 (3)
Phase 1Mantle Cell LymphomaRecruiting
Est. primary completion 2028-07 · NCT05990465 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, PirtobrutinibNot yet recruiting
Est. primary completion 2028-07-31 · NCT07744724 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-07-31 · NCT06252675 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Pirtobrutinib, Sintilimab, Central Nervous System LymphomaRecruiting
Est. primary completion 2028-08-05 · NCT07416890 · CT.gov ↗
What to watch
Phase 2DLBCLNot yet recruiting
Est. primary completion 2028-08-25 · NCT07774299 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2028-09-01 · NCT07624799 · CT.gov ↗
What to watch
Phase 2Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic LymphomaNot yet recruiting
Est. primary completion 2028-09-01 · NCT07812493 · CT.gov ↗
What to watch
Phase 2DLBCL - Diffuse Large B Cell LymphomaRecruiting
Est. primary completion 2028-09-30 · NCT07255963 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-10-30 · NCT07684950 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-11-01 · NCT06263491 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2028-12-08 · NCT07944651 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07052695 · CT.gov ↗
What to watch
Phase 2PCNSL, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT07350850 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 2Waldenstrom MacroglobulinemiaActive not recruiting
Est. primary completion 2029-01-25 · NCT05734495 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-05 · NCT06812715 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-08 · NCT06553872 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-10 · NCT07516093 · CT.gov ↗
What to watch
2030 (8)
February 2030 (1)
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2030-02-01 · NCT07428707 · CT.gov ↗
What to watch
May 2030 (5)
Phase 2Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell LymphomaActive not recruiting
Est. primary completion 2030-05 · NCT07162181 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2030-05 · NCT06876662 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2030-05 · NCT06876649 · CT.gov ↗
What to watch
Phase 4Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2030-05 · NCT07218341 · CT.gov ↗
What to watch
Phase 2Richter TransformationRecruiting
Est. primary completion 2030-05-15 · NCT07917780 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2030-10-15 · NCT07860775 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Richter SyndromeNot yet recruiting
Est. primary completion 2030-12-31 · NCT07831395 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2031-06-01 · NCT06967610 · CT.gov ↗
What to watch
July 2031 (1)
Phase 2Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma …Recruiting
Est. primary completion 2031-07-31 · NCT06948786 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Marginal Zone LymphomaRecruiting
Est. primary completion 2031-12 · NCT06390956 · CT.gov ↗
What to watch
2032 (2)
April 2032 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2032-04 · NCT05833763 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2032-12 · NCT07285590 · CT.gov ↗
What to watch
2034 (1)
November 2034 (1)
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2034-11 · NCT07548450 · CT.gov ↗
What to watch
2035 (1)
October 2035 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2035-10-01 · NCT07220187 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 October 2026ApprovalFDA approves Jaypirca for previously untreated CLL/SLL
US, FDA · Eli Lilly and Company · Source ↗
September 2026ApprovalNMPA approves Jaypirca for CLL/SLL across all lines of therapy in China
CN, NMPA · Innovent Biologics, Inc. · Source ↗
7 December 2025Topline resultBRUIN CLL-314 Phase 3 meets primary endpoint vs ibrutinib
3 December 2025ApprovalFDA approves expanded Jaypirca indication in R/R CLL/SLL
US, FDA · Source ↗
8 September 2025Topline resultBRUIN CLL-313 Phase 3 topline: pirtobrutinib improves PFS vs bendamustine plus rituximab
29 July 2025Topline resultPhase 3 BRUIN CLL-314 of pirtobrutinib versus ibrutinib met its primary endpoint
Eli Lilly · Source ↗
9 December 2024Topline resultBRUIN CLL-321 Phase 3 final analysis results